Delivery Order SPE2DB22D3011-SPE2DB25FQ2VM
- Not listed
- The Defense Logistics Agency awarded a $15,269.80 firm fixed price delivery order to AmerisourceBergen Drug Corp for Mounjaro 2.5 mg/0.5 mL pens on August 11, 2025, with an ultimate completion date of August 12, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical will be delivered to the company's...
- The Defense Logistics Agency awarded a $2,776.41 delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens on September 22, 2025, with completion targeted for September 23, 2025. This is a firm fixed price, non-set-aside contract with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a $26,741.23 delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 2.5 mg/0.5 mL pens on September 3, 2025, with completion scheduled for September 4, 2025. This firm fixed-price, non-set-aside contract represents a routine pharmaceutical procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle valued through...
- The Defense Logistics Agency awarded a delivery order valued at $3,437.98 to AmerisourceBergen Drug Corp on July 17, 2025, for the supply of Mounjaro 5 mg/0.5 mL pens (0.5 mL units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 18, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control, aligning with AmerisourceBergen's extensive portfolio of...
- The Defense Logistics Agency awarded a $1,088.36 delivery order to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 mL pens on June 17, 2025, with an ultimate completion date of June 18, 2025. This firm fixed price, competitively awarded contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Mounjaro is a prescription medication used for diabetes management, consistent with AmerisourceBergen's extensive portfolio of...
- The Defense Logistics Agency awarded a $2,239.89 delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 mL pens on September 2, 2025, with completion scheduled for September 3, 2025. This competitive award utilizes firm fixed pricing and represents a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency awarded a $39,675.61 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 12.5 mg/0.5 mL pens on September 4, 2025, with an ultimate completion date of September 5, 2025. This is a non-set-aside competitive award issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,681.38 to AmerisourceBergen Drug Corp for Mounjaro 15 mg/0.5 mL pens on August 29, 2025, with completion expected by September 2, 2025. This competitively awarded, firm fixed-price delivery order requires fulfillment at AmerisourceBergen's Conshohocken, Pennsylvania location and represents no set-aside designation. Mounjaro is a prescription medication used for diabetes management, consistent with AmerisourceBergen's role...
- The Defense Logistics Agency awarded a $3,381.47 delivery order to AmerisourceBergen Drug Corp for Mounjaro 2.5 mg/0.5 mL pens on June 20, 2025, with completion expected by June 23, 2025. This firm fixed-price contract represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control, aligning with AmerisourceBergen's extensive portfolio of pharmaceutical products supplied...
- The Defense Logistics Agency awarded a $16,757.06 delivery order to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 mL pens on April 22, 2025, with completion scheduled for April 23, 2025. This competitively awarded, firm fixed-price delivery order was placed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside designation, and...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2VMDelivery Order
The Defense Logistics Agency awarded a $32,650.80 delivery order to AmerisourceBergen Drug Corp for Mounjaro 15 mg/0.5 mL pens on September 19, 2025, with completion expected by September 22, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control in patients with type 2 diabetes, reflecting the company's extensive role in supplying pharmaceutical products to federal healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a critical pharmaceutical prime vendor for the Defense Logistics Agency, AmerisourceBergen supplies a comprehensive range of medications and medical commodities to support military healthcare programs globally, including the Defense Health Agency and U.S. Coast Guard. The company's established vendor status and competitive positioning demonstrate its capability to fulfill federal medical supply requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $32.7k | 9/19/25 |